Royalty Pharma PLC
NASDAQ:RPRX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
24.28
40.5542
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Operating Margin
Royalty Pharma PLC
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Royalty Pharma PLC
NASDAQ:RPRX
|
22.4B USD |
65%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
957.6B USD |
44%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
506.9B USD |
27%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
251.8B CHF |
34%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
207.6B GBP |
24%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
202.5B CHF |
33%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
248.2B USD |
38%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
42%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
206B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
146.9B USD |
29%
|
Royalty Pharma PLC
Glance View
Royalty Pharma PLC operates within a unique niche of the pharmaceutical industry, using a business model that might seem more akin to financial engineering than traditional drug development. Founded by Pablo Legorreta in 1996, the company has carved out a role as a specialized investment entity, acquiring pharmaceutical royalties from innovative biopharmaceutical companies. Essentially, Royalty Pharma provides capital to these firms upfront or participates in funding their development projects, and in return, it earns a slice of the future sales of the companies' drugs. This strategy makes Royalty Pharma a distinct player that benefits indirectly from the pharmaceutical market's successes while largely sidestepping the substantial risks associated with drug development. The company thrives on a diversified portfolio of royalties spanning numerous therapeutic areas, including rare diseases, oncology, and neurology, among others. This diversification mitigates risk and offers a stable cash flow pattern, as the success of one drug can offset challenges faced by another. Notably, Royalty Pharma’s earnings are impacted by the performance of highly successful drugs like Vertex’s cystic fibrosis therapies and Janssen’s cancer drug Imbruvica. By tapping into the promising prospects of life-saving and high-demand pharmaceutical innovations, it has created a profitable loop of continuous royalty accrual, translating clinical triumphs into financial well-being. Through this model, Royalty Pharma positions itself as a kingmaker, enabling biopharma to reach groundbreaking milestones while collecting revenue as these therapies transform the healthcare landscape.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Royalty Pharma PLC's most recent financial statements, the company has Operating Margin of 65.2%.